|
시장보고서
상품코드
2091277
재발성 두경부 편평상피암 시장 규모, 점유율, 성장 분석 : 치료법별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Size, Share, and Growth Analysis, By Treatment Type (Chemotherapy, Immunotherapy), By Route of Administration (Intravenous, Oral), By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 재발성 두경부 편평상피암 시장 규모는 2024년에 30억 9,000만 달러로 평가되었으며, 2025년 33억 1,000만 달러에서 2033년까지 57억 8,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 7.2%로 성장할 것으로 전망됩니다.
재발성 두경부 편평상피암(HNSCC) 세계 시장은 흡연, 음주, 인유두종바이러스(HPV) 감염 증가와 같은 요인으로 인한 발병률 상승에 힘입어 눈부신 성장을 이루고 있습니다. 초기 치료 후 재발률이 높기 때문에 효과적인 2차 치료 및 구제 요법에 대한 수요가 지속적으로 발생하고 있습니다. 면역요법, 특히 면역관문억제제 및 분자 표적 요법의 발전으로 인해, 점점 늘어나는 환자층을 위한 치료 선택지가 확대되고 있습니다. 바이오마커 검사 및 분자 프로파일링에 힘입어 정밀 의학으로의 전환은 치료의 개인화를 촉진하고, 결과적으로 환자의 예후를 개선하고 있습니다. 동시에, 암 연구에 대한 투자 확대, 치료제 파이프라인 확충, 그리고 AI를 활용한 진단 도구의 통합을 통해 치료 과정이 합리화되고, 재발의 조기 발견이 촉진되며, 시장 역학이 활성화되고 있습니다.
세계 재발성 두경부 편평상피암 시장은 치료 유형, 투여 경로, 최종사용자 및 지역별로 분류됩니다. 치료 유형에 따라 시장은 화학요법, 면역요법, 분자 표적 치료, 방사선 요법 및 기타로 구분됩니다. 투여 경로별로는 정맥내 투여와 경구 투여로 분류됩니다. 최종사용자별로는 병원, 종양 클리닉, 연구 기관으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분류됩니다.
세계 재발성 두경부 편평상피암 시장의 성장요인
세계 재발성 두경부 편평상피암 시장은 면역요법제의 도입 확대에 힘입어 눈부신 성장을 이루고 있습니다. 임상의들은 기존의 화학방사선요법과 비교했을 때, 이러한 혁신적인 치료법들이 생존율을 높이고 발병률을 최소화할 가능성이 있음을 점차 인식하고 있습니다. 이러한 치료 접근 방식의 전환에 따라, 제약 기업의 신제제 개발에 대한 투자가 활발해지고 있으며, 임상시험 활동도 활발해지고 있습니다. 그 결과, 승인된 치료 옵션의 폭이 넓어져 환자분들께 더욱 맞춤형 치료 경로를 제공할 수 있게 되었습니다. 이는 결과적으로 전문적인 투여 서비스 및 동반진단 검사에 대한 수요를 높이며, 종양학 네트워크 전반에 걸친 임상적 신뢰도 향상과 환자들의 선호에 힘입어 시장 확대의 선순환을 만들어내고 있습니다.
세계 재발성 두경부 편평상피암 시장의 제약요인
표적 치료에 수반되는 막대한 비용은, 특히 환급 절차가 복잡하거나 제한적인 환경에서, 다양한 의료 시스템 내에서의 광범위한 도입에 큰 걸림돌이 되고 있습니다. 높은 가격 책정은 환자의 접근성을 제한하며, 비용 대비 효과에 대한 설득력 있는 증거가 없는 한, 보험사는 새로운 치료법의 승인을 신중하게 검토하는 경향이 있습니다. 그 결과, 의료 서비스 제공자들은 기존 치료법에 계속 의존하게 될 가능성이 있으며, 이는 혁신적인 치료법의 시장 침투를 저해하게 될 것입니다. 게다가 이러한 경제적 부담은 투자 의욕을 저하시켜, 결과적으로 치료 환경의 발전을 저해하고, 궁극적으로는 시장의 성장을 제한하며, 환자의 예후에 악영향을 미칩니다.
세계 재발성 두경부 편평상피암 시장의 동향
세계 재발성 두경부 편평상피암 시장은 면역요법이 표준 치료 프로토콜에 포함됨에 따라 큰 변화를 겪고 있습니다. 체크포인트 억제제나 세포 이식 요법의 적용이 늘어나고 있으며, 임상의들이 이러한 혁신적인 치료법을 방사선 치료나 화학요법과 같은 기존 치료법과 병행하는 사례가 증가함에 따라 치료 양상이 변화하고 있습니다. 이러한 추세는 시너지 효과를 보여주는 새로운 임상적 근거와, 환자 및 의료 제공자들 사이에서 더 효과적이고 독성이 낮은 치료법에 대한 선호도가 높아지고 있는 점에 힘입어 가속화되고 있습니다. 각 제약사는 이에 대응하여 면역종양학 연구에 더욱 주력하는 한편, 전 세계적인 차원의 선진적인 임상시험을 위한 협력을 촉진함으로써 치료 환경 전반의 개선을 도모하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 재발성 두경부 편평상피암 시장 규모 : 치료 유형별
세계의 재발성 두경부 편평상피암 시장 규모 : 투여 경로별
세계의 재발성 두경부 편평상피암 시장 규모 : 최종사용자별
세계의 재발성 두경부 편평상피암 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market size was valued at USD 3.09 Billion in 2024 and is poised to grow from USD 3.31 Billion in 2025 to USD 5.78 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).
The global market for recurrent head and neck squamous cell carcinoma (HNSCC) is experiencing significant growth fueled by rising incidence rates influenced by factors such as tobacco use, alcohol consumption, and increasing human papillomavirus (HPV) infections. High recurrence rates post-initial treatment have created a consistent demand for effective second-line and salvage therapies. Advancements in immunotherapy, particularly immune checkpoint inhibitors and targeted therapies, are broadening treatment options for an expanding patient population. The shift towards precision medicine, driven by biomarker testing and molecular profiling, enhances therapy customization, thereby improving patient outcomes. Concurrently, increased investment in oncology research, an expanding pipeline of therapeutics, and the integration of AI-driven diagnostic tools are streamlining treatment pathways, facilitating early recurrence detection, and enhancing overall market dynamics.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Segments Analysis
The global recurrent head and neck cancer squamous cell carcinoma market is segmented by treatment type, route of administration, end user and region. Based on treatment type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Drug Therapy, Radiation Therapy and Others. Based on route of administration, the market is segmented into Intravenous and Oral. Based on end user, the market is segmented into Hospitals, Oncology Clinics and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
The global market for recurrent head and neck cancer squamous cell carcinoma is witnessing significant growth driven by the increasing adoption of immunotherapy agents. Clinicians are recognizing the potential of these innovative treatments to enhance survival rates and minimize morbidity relative to traditional chemoradiation therapies. This shift in therapeutic approach has spurred greater investment from pharmaceutical companies in developing new formulations and bolstered clinical trial activity. Consequently, a broader range of approved treatment options is emerging, enabling more personalized care pathways for patients. This, in turn, escalates the demand for specialized administration services and companion diagnostic testing, creating a self-perpetuating cycle of market expansion fueled by heightened clinical confidence and patient preferences across oncology networks.
Restraints in the Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
The significant expense associated with targeted therapies poses a substantial barrier to widespread adoption within various healthcare systems, especially in environments where reimbursement processes are complicated or limited. High pricing restricts patient access, leading payers to be cautious about endorsing newer treatment options without compelling evidence of cost-effectiveness. Consequently, healthcare providers may continue to rely on traditional treatment approaches, hampering the market penetration of innovative therapies. Additionally, this financial burden diminishes the incentive for investment, which in turn hinders the advancement of the therapeutic landscape, ultimately constraining market growth and negatively impacting patient outcomes.
Market Trends of the Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
The global recurrent head and neck squamous cell carcinoma market is witnessing a significant transformation driven by the integration of immunotherapies into standard treatment protocols. The rising application of checkpoint inhibitors and adoptive cell therapies is changing the landscape, as clinicians increasingly combine these innovative therapies with traditional modalities like radiation and chemotherapy. This trend is propelled by emerging clinical evidence indicating synergistic benefits and a growing preference among patients and healthcare providers for more effective, less toxic treatment options. Pharmaceutical companies are responding by intensifying their focus on immuno-oncology research and fostering collaborations for advanced clinical trials globally, thereby enhancing the overall therapeutic landscape.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Chemotherapy
- Platinum-Based
- Docetaxel
- Others
- Immunotherapy
- PD-1/PD-L1 Inhibitors
- CTLA-4 Inhibitors
- Targeted Drug Therapy
- EGFR Inhibitors
- Others
- Radiation Therapy
- Others
Global Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous
- Oral
Global Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Oncology Clinics
- Research Institutes
Global Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Size & CAGR (2026-2033)
- North America (Treatment Type, Route of Administration, End User)
- US
- Canada
- Europe (Treatment Type, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Roche Holding AG (Genentech)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celldex Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Iterion Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cohesion Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oncobiologics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Seagen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioNTech SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
